Welcome to our dedicated page for Harmony Biosciences Holdings news (Ticker: HRMY), a resource for investors and traders seeking the latest updates and insights on Harmony Biosciences Holdings stock.
Harmony Biosciences Holdings, Inc. develops and commercializes therapies for rare neurological diseases, with WAKIX® (pitolisant) as its commercial product for adult narcolepsy-associated cataplexy. News about HRMY centers on WAKIX revenue trends, market access and payer dynamics, intellectual-property protection, and product guidance.
Company updates also cover clinical and regulatory progress across its CNS pipeline, including pitolisant lifecycle programs and candidates such as EPX-100 for Dravet syndrome and Lennox-Gastaut syndrome. Recurring announcements include quarterly results, investor-conference presentations, executive and board changes, and pipeline data presentations at medical meetings.
Harmony Biosciences Holdings, based in Plymouth Meeting, PA, will present a company update at the 21st Annual Needham Virtual Healthcare Conference on April 11, 2022. CEO John C. Jacobs will lead a fireside chat from 12:45 p.m. to 1:25 p.m. ET and participate in 1x1 meetings on the same day. Investors can access a webcast of the chat on Harmony's investor page. Harmony focuses on innovative therapies for rare neurological diseases, aiming to address unmet medical needs.
Harmony Biosciences (Nasdaq: HRMY), a pharmaceutical company focused on rare neurological diseases, has been recognized as a Great Place to Work for the fourth consecutive year, reflecting positive employee feedback on workplace culture. This recognition is based on employee surveys evaluating management, innovation, communication, and diversity. CEO John C. Jacobs emphasized that this accolade highlights the company's commitment to fostering teamwork and a fulfilling work experience, which ultimately enhances their mission to improve the lives of patients.
Harmony Biosciences announced the opening of applications for its Patients at the Heart Program on March 18, 2022, supporting nonprofit organizations addressing challenges faced by individuals with rare neurological diseases, particularly those experiencing excessive daytime sleepiness (EDS). Since its launch in 2019, the program has awarded over $230,000 to patient-centric initiatives. The 2022 application periods are March 18 to May 20 and May 31 to August 19. Harmony aims to enhance community support for patients and their families.
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) announced its participation in two upcoming virtual conferences. The events include the Oppenheimer 32nd Annual Healthcare Conference on March 15, 2022, featuring a fireside chat from 2:40 p.m. to 3:10 p.m. ET, and 1st Annual Needham Virtual Neuroscience Forum on March 16, 2022, with a fireside chat from 8:45 a.m. to 9:25 a.m. ET. A webcast of these events will be available on Harmony's investor page.
Harmony Biosciences (HRMY) reported Q4 2021 net revenue of $91.2 million, a 62% increase year-over-year, and full-year revenue of $305.4 million, up 91%. The company achieved its first full year of profitability with net income of $22.7 million in Q4. An average of 3,800 patients were on WAKIX, driving strong demand. The Phase 3 trial for Idiopathic Hypersomnia is set to begin in H1 2022. As of year-end 2021, cash reserves stood at approximately $234 million.
Harmony Biosciences (Nasdaq: HRMY) will announce its fourth quarter and full year 2021 financial results on February 28, 2022. A conference call will follow at 8:30 a.m. ET. Investors can participate by dialing (833) 614-1471 domestically or +1 (914) 987-7209 internationally, using passcode 7277008. A replay of the call will be available within 24 hours. Harmony Biosciences focuses on innovative treatments for rare neurological diseases. For more information, visit their website.
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) announced that President and CEO John C. Jacobs will present a company update at the 40th Annual J.P. Morgan Healthcare Conference on January 13, 2022, at 7:30 AM ET. Investor meetings are scheduled from January 10 to January 13, 2022. A webcast of the presentation will be available on the investor page of Harmony's website. Harmony Biosciences focuses on innovative therapies for patients with rare neurological diseases. For more information, visit www.harmonybiosciences.com.
Harmony Biosciences, a pharmaceutical company focused on rare neurological diseases, will be added to the NASDAQ Biotechnology Index on December 20, 2021. This inclusion reflects the company's progress in 2021 and highlights its commitment to innovative treatments. The NASDAQ Biotechnology Index tracks the performance of biotechnology and pharmaceutical companies listed on NASDAQ. Harmony's CEO, John C. Jacobs, stated that this achievement will enhance visibility with investors. The company aims to continue its growth and innovation in the rare neurological disease space.
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) announced the publication of a data analysis in CNS Drugs, focusing on the efficacy of pitolisant for treating excessive daytime sleepiness (EDS) and cataplexy in narcolepsy patients. The analysis, derived from two Phase 3 trials, indicates that the response to pitolisant generally begins within the first 2-3 weeks, with significant improvements noted in the Epworth Sleepiness Scale and weekly cataplexy rates. The study reinforces pitolisant's role as an effective treatment option for narcolepsy.
Harmony Biosciences (HRMY) announced that the FDA has accepted its IND application for pitolisant to treat idiopathic hypersomnia (IH). A Phase 3 clinical trial is planned for the first half of 2022, focusing on evaluating the drug's safety and efficacy in adults. This move aims to expand pitolisant's use beyond narcolepsy, potentially addressing the needs of 30,000 to 40,000 IH patients in the U.S. Harmony is responding to significant interest from the medical community and aims to provide new treatment options for this rare neurological disorder.